BLUESTAR GENOMICS

Bluestar Genomics is spearheading the development and commercialization of epigenomic non-invasive cancer tests to detect the deadliest cancers earlier than existing methods. Starting with pancreatic cancer, our aim with these tests is to detect the disease early when therapies are most effective... Bluestar Genomics focuses on cancers with high mortality rates for which there are no or very limited screening options... Bluestar Genomics develops liquid biopsy diagnostic tests based on its proprietary epigenomics platform to detect cancers with high mortality rates early when they respond best to treatment.

Also known as: Bluestar Genomics, Inc.

Primary location: San Mateo United States